Search Results - thomas+schmitt

2 Results

Sort By:

NKG2D-SCD-T-Engager

Therapeutics targeting NKG2D ligands for elimination of cancer cells and senescent cells A novel fusion protein targeting NKG2D ligands for eradicating cancer and senescent cells. Natural killer group 2 member D ligands (NKG2DLs) are consistently upregulated in cancer cells, senescent cells, and cells undergoing genotoxic stress. Moreover,...

Published: 5/15/2025 | Updated: 3/10/2024 | Inventor(s): Thomas Schmitt, Roland Strong

Keywords(s): Immuno Oncology

Category(s): Therapeutic

High Affinity MAGE-A1 T-cell Receptors

TCR Cell Therapy Targeting MAGE-A1 High-affinity MAGE-A1-specific TCR for the treatment of multiple myeloma and solid tumors. The MAGE family are CTAs expressed in many tumor types and MAGE-A1 has been shown to directly drive tumorigenesis. Specifically, MAGE-A1 is expressed in about 50% of multiple myeloma, up to 60% in triple negative...

Published: 5/15/2025 | Updated: 1/19/2023 | Inventor(s): Aude Chapuis, Thomas Schmitt, Megan McAfee

Keywords(s): Immuno Oncology, Target

Category(s): Cell Therapy, Therapeutic